Cours Tilray, Inc. Toronto S.E.
Actions
APHA
CA03765K1049
Produits pharmaceutiques
CA 2024 * | 783 M 1,07 Md 710 M | CA 2025 * | 864 M 1,18 Md 783 M | Capitalisation | 1,56 Md 2,13 Md 1,41 Md |
---|---|---|---|---|---|
Résultat net 2024 * | -226 M -309 M -205 M | Résultat net 2025 * | -85 M -116 M -77,06 M | VE / CA 2024 * | 2,22 x |
Dette nette 2024 * | 178 M 244 M 161 M | Dette nette 2025 * | 108 M 148 M 98,37 M | VE / CA 2025 * | 1,93 x |
PER 2024 * |
-5,87
x | PER 2025 * |
-13,6
x | Employés | 1 600 |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 98,73% |
Dernier transcript sur Tilray, Inc.
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 30/04/21 |
Carl Merton
DFI | Director of Finance/CFO | - | 30/04/21 |
Lloyd Brathwaite
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/21 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 30/04/21 |
David Clanachan
BRD | Director/Board Member | 62 | 30/04/21 |
Walter Robb
BRD | Director/Board Member | 70 | 30/04/21 |
Varia. 1 janv. | Capi. | |
---|---|---|
+30,38% | 684 Md | |
+26,51% | 568 Md | |
-4,36% | 361 Md | |
+19,30% | 329 Md | |
+3,73% | 284 Md | |
+16,70% | 240 Md | |
+8,78% | 208 Md | |
-7,93% | 200 Md | |
+7,68% | 166 Md |